Xocova belongs to the same class of drugs as Pfizer’s Paxlovid and Merck’s Lagevrio, which are used to help prevent severe cases of COVID-19. More on Shionogi & Co. Shionogi & Co. reports H1 ...

Shionogi’s did just that. Reshma Ramachandran, a family physician at Yale, told me that if the early Xocova results hold up in additional trials, she’d be inclined to prescribe it to her ...

While Xocova came later to the market than Shionogi initially hoped for after Japanese regulators twice requested more data, the company says interim results of a study suggest taking the pill ...

Shionogi recently presented results from the ... About ensitrelvir Ensitrelvir (known in Japan as Xocova ®), an oral antiviral drug for COVID-19, is currently approved under the emergency ...

Outside Japan, Xocova is also approved in Singapore. Sanofi keeps Novavax afloat with $1.2B bet on its vaccine platform Despite the misfire in SCORPIO-HR, Shionogi said that a pre-defined ...

Shionogi’s COVID-19 treatment Xocova was found to reduce the risk of developing at least one of the symptoms of long COVID-19, the Osaka-based pharmaceutical company said Wednesday. Shionogi ...

Ensitrelvir, known commercially as Xocova, showed a statistically significant reduction in participants with symptomatic infection after exposure to household contacts with COVID, Shionogi said in ...

The win goes to local drugmaker Shionogi, which has clinched an emergency approval for its oral antiviral Xocova from Japan’s Ministry of Health, Labour and Welfare (MHLW) to treat SARS-CoV-2 ...

Shionogi & Co.’s Covid pill could be approved ... The Japanese drugmaker has been submitting data to regulators in China and expects Xocova to be authorized for use as early as this quarter ...

The oral drug Xocova marks the first home-grown medication, developed by Shionogi & Co., which can be prescribed for patients with mild symptoms, suggesting a stable supply of the tablet will be ...

TOKYO, May 13 (Reuters) - Japan's Shionogi & Co (4507.T), opens new tab said on Monday its pill-based treatment for COVID-19 did not meet the primary endpoint of showing a statistically ...

Japanese drugmaker Shionogi (OTCPK:SGIOY) said a Phase 3 study has shown its antiviral drug Xocova was effective in reducing the risk of developing symptomatic COVID-19 infection in those exposed ...